Skip to content

A clinical trial to study the effects of two drugs, Lornoxicam and Ibuprofen in moderate to severe menstrual cramping pain due to primary dysmenorrhoea

Comparative Efficacy, Safety and Cost Effectiveness of Lornoxicam with Ibuprofen in Patient with Primary Dysmenorrhoea : A Randomized, Double-Blind, Active-Controlled Study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/12/002188
Enrollment
75
Registered
2011-12-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N944- Primary dysmenorrhea Health Condition 2: null- primary dysmenorrhoea

Interventions

Intervention1: Lornoxicam: Lornoxicam 8mg twice a day for 3 days of moderate to severe menstrual cycle Control Intervention1: Lornoxicam and Ibuprofen: Ibuprofen 400mg BD for 3 days Lornoxicam 8mg

Sponsors

Government Medical College Bhavnagar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ?Healthy women of 18 to 40 years of age groups ?Regular menstrual cycle (21 ? 35 days) ?With moderate or severe pain and self assessment of dysmenorrhoea ?History of primary dysmenorrhoea within 3 to 4 years of menarche ?Willing for non pregnant status during entire study period ?History of at least 6 month of menstrual cramping pain which last for 2 days of each menstrual cycle ?Patient who voluntary participate in the study with signed inform consent

Exclusion criteria

Exclusion criteria: ?Patient having secondary dysmenorrhoea ?Patient having mild menstrual pain ?Patient with any valvular heart disease or acute abdominal condition ?Patient with history of severe gastritis, peptic ulceration or any g.i.t bleeding ?Patient taking regular NSAIDs for some therapeutic indication for pain relief other than menstrual pain ?Patient underwent for some surgical procedure or IUD insertion or injectable contraceptive before the 4 month of study ?Patient allergic to any NSAIDs ?Patient on ACE inhibitors, platelet aggregation inhibitors, diuretics or anti diabetic drugs ?Taking rescue medication within the 1 hour of trial medication during study

Design outcomes

Primary

MeasureTime frame
Total pain relief scoreTimepoint: 2,4,6,8, 12, 24, 72 hours after post dose

Secondary

MeasureTime frame
â?¢ Safety and tolerability of will be assessed by the number of patients with clinical adverse experiencesTimepoint: At the end of the study

Countries

India

Contacts

Public ContactDr Jayshree Chimanbhai Patel

Government Medical College, Bhavnagar

dr_jayshreepatel@yahoo.com09558177380

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026